title: Differentiation of EL4 lymphoma cells by tumoral environment is associated with inappropriate expression of the large chondroitin sulfate proteoglycan PG-M and the tumor-associated antigen HTgp-175.
abstract: Progression to malignancy of transformed cells involves complex genetic alterations and aberrant gene expression patterns. While aberrant gene expression is often caused by alterations in individual genes, the contribution of the tumoral environment to the triggering of this gene expression is less well established. The stable but heterogeneous expression in cultured EL4/13 cells of a novel tumor-associated antigen, designated as HTgp-175, was chosen for the investigation of gene expression during tumor formation. Homogeneously HTgp-175-negative EL4/13 cells, isolated by cell sorting or obtained by subcloning, acquired HTgp-175 expression as a result of tumor formation. The tumorigenicity of HTgp-175-negative vs. HTgp-175-positive EL4 variants was identical, indicating that induction but not selection accounted for the phenotypic switch from HTgp-175-negative to HTgp-175-positive. Although mutagenesis experiments showed that the protein was not essential for tumor establishment, tumor-derived cells showed increased malignancy, linking HTgp-175 expression with genetic changes accompanying tumor progression. This novel gene expression was not an isolated event, since it was accompanied by ectopic expression of the large chondroitin sulfate proteoglycan PG-M and of normal differentiation antigens. We conclude that signals derived from the tumoral microenvironment contribute significantly to the aberrant gene expression pattern of malignant cells, apparently by fortuitous activation of differentiation processes and cause expression of novel differentiation antigens as well as of inappropriate tumor-associated and ectopic antigens.
authors.affiliation: Department of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Ghent, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Rottiers
authors.forename: T
authors.initials: T
authors.lastname: Verfaillie
authors.forename: R
authors.initials: R
authors.lastname: Contreras
authors.forename: H
authors.initials: H
authors.lastname: Revets
authors.forename: M
authors.initials: M
authors.lastname: Desmedt
authors.forename: H
authors.initials: H
authors.lastname: Dooms
authors.forename: W
authors.initials: W
authors.lastname: Fiers
authors.forename: J
authors.initials: J
authors.lastname: Grooten
mesh_terms: D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000235:genetics*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics; D002454:Cell Differentiation / Q000235:genetics*; D002460:Cell Line; D011508:Chondroitin Sulfate Proteoglycans / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D008223:Lymphoma / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D014407:Tumor Cells, Cultured; D053675:Versicans
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D011508:Chondroitin Sulfate Proteoglycans; C508323:Vcan protein, mouse; D053675:Versicans